Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

109results about How to "Prevents or" patented technology

Transdermal delivery of systemically active central nervous system drugs

The invention relates to a transdermal or transmucosal non-occlusive, semi-solid pharmaceutical formulation that includes at least one systemically active agent that acts on the Central Nervous System (CNS) of a mammal; and a permeation enhancing solvent system present in an amount sufficient to solubilize the at least one active ingredient. The permeation enhancing solvent system includes a pharmaceutically acceptable monoalkyl ether of diethylene glycol; a pharmaceutically acceptable glycol; preferably also a fatty alcohol and or a fatty acid; and a mixture of a C2 to C4 alcohol and water so that the permeation enhancing solvent system (a) inhibits crystallization of the at least one active ingredient on a skin or mucosal surface of a mammal, (b) reduces or prevents transfer of the formulation to clothing or to another being, (c) modulates biodistribution of the at least one active agent within different layers of skin, (d) facilitates absorption of the at least one active agent by a skin or a mucosal surface of a mammal, or (e) provides a combination of one or more of (a) through (d).
Owner:ANTARES PHARMA IPL

Catheter package

PCT No. PCT / SE97 / 01033 Sec. 371 Date Jul. 29, 1997 Sec. 102(e) Date Jul. 29, 1997 PCT Filed Jun. 12, 1997 PCT Pub. No. WO97 / 47349 PCT Pub. Date Dec. 18, 1997A catheter package (10; 110; 210) comprising a catheter (1; 101; 201) positioned within an inner container (2; 102; 202) permeable to a sterilizing agent, for example an ethylene oxide gas. An outer container (3; 103; 203) which prevents access of moisture to the interior thereof encloses the inner container and catheter assembly. Two or more catheters may be stored in individual inner containers within the outer container.
Owner:ASTRAZENECA AB

Systems and methods of blood-based therapies having a microfluidic membraneless exchange device

InactiveUS20080009780A1PreventsMinimize bioincompatibilitiesSamplingOther blood circulation devicesAmount of substanceThin layer
The present invention is directed to devices, systems and methods for removing undesirable materials from a sample fluid by contact with a second fluid. The sample fluid flows as a thin layer adjacent to, or between, concurrently flowing layers of the second fluid, without an intervening membrane. In various embodiments, a secondary separator is used to restrict the removal of desirable substances and effect the removal of undesirable substances from blood. The invention is useful in a variety of situations where a sample fluid is to be purified via a diffusion mechanism against an extractor fluid. Moreover, the invention may be used for the removal of components from a sample fluid that vary in size. When blood is the sample fluid, for example, this may include the removal of ‘small’ molecules, ‘middle’ molecules, macromolecules, macromolecular aggregates, and cells, from the blood sample to the extractor fluid.
Owner:COLUMBIA UNIV (US)

Hem flange joint

The present invention relates to a method of producing an edging-fold bond. For this purpose use is made more particularly of high-viscosity adhesives. The method features reduced bubble formation within the edging fold and also within the sealant (where present) that seals the edging-fold seam. More particularly the adhesive comprises spacers which further reinforce this effect.
Owner:SIKA TECH AG

Stabilized filament drawing device for a meltspinning apparatus

A stabilized filament drawing device for a meltspinning apparatus. The stabilized filament drawing device applies a high-velocity flow of air to attenuate the filaments, which are discharged from a device outlet in a discharge direction. The filament drawing device includes multiple inclined guides adjacent to the outlet that cause the high-velocity flow of air to deviate from the discharge direction by the Coanda effect. The filaments, which are entrained in the high-velocity process air, likewise deviate from the discharge direction. The guides are arranged such that spaces are absent between adjacent guides.
Owner:OERLIKON TEXTILE GMBH & CO KG

Needle catheter with an angled distal tip lumen

A needle catheter configured for injecting an agent into a wall of a patient's body cavity, which directs a needle from the distal tip of the catheter into the wall of the body cavity at an angle relative to the axis of the shaft. The resulting angled injection pathway improves the retention of the agent in the body cavity wall, while keeping a distal section of the catheter substantially perpendicular to the body cavity wall for optimal push against the tissue at the injection site.
Owner:ABBOTT CARDIOVASCULAR
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products